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Abstract 
Introduction: Parkinson’s disease (PD) is one of the common disorders in the central nervous system. Among non-motor symptoms, fatigue 
is the most widespread one with prevalence rates of 40-65 that can have an impact on the quality of life of patients. The aim of this study was to 
evaluate the validity and the reliability of the Persian version of Parkinson Fatigue Scale (PFS-16). Materials and Methods: 70 patients with PD 
(mean age: 62.7±11.6) participated in this study through non-probability and available sampling method. Test-retest reliability and internal 
consistency were used to measure the reliability and the Fatigue Severity Scale (FSS), Parkinson's disease questionnaire (PDQ-8) and Visual 
Analogue fatigue Scale (VAS-F) were employed to measure the criteria validity. Results: Cronbach's alpha and ICC of the Persian version of 
PFS-16 were both measured to be 0.97. In addition, Kappa coefficient for each item of the scale was measured to be between 0.76 and 1.00, 
which indicated a very good level of reliability. Correlations between PFS-16 and FSS, PDQ-8 and VAS-F were estimated to be 0.58, 0.51 and 
0.49, respectively. Conclusion: Results indicated high reliability and the validity of Persian-version of the mentioned scale. Therefore, its 
application in related studies is highly recommended. 
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Introduction 
Parkinson's disease (PD) is recognized as the second most 
common neurodegenerative disorder after Alzheimer's disease 
(1). The main symptoms of PD include bradykinesia, resting 
tremor and rigidity (2). Moreover, patients with PD usually 
report non-motor symptoms which besides motor problems 
could prominently affect patients' quality of life (3, 4). Among 
the non-motor symptoms, fatigue is the most common 
problem which is present in 40-65% of the patients with PD 
(5). Fatigue which is an umbrella term for a variety of complex 
symptoms could occur following the neurological, systematic 
and cognitive disorders. Fatigue is defined as the subjective 
feeling of inability, loss of energy and extreme exhaustion that 
also overlaps with insomnia definition (6). In addition, fatigue 
is closely associated with depression which is distinct from 
depression resulting from neurological disorders. This non-
motor problem (fatigue) is often considered as an indication in 
the early stages of the disease and may antedate the 
development of motor symptoms for several months (7, 8). 
It is worth mentioning that, appropriate application of the 
intervention protocols could facilitate the improvement 
process of patients with PD and reduce the negative 
consequences of motor and non-motor problems of patients 
with PD, their caregivers and the society. In order to apply the 
intervention protocols, appropriate and accurate tools to 
measure the symptoms and the outcomes are absolutely 
essential. Moreover, as fatigue has a significantly negative 
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impact on the quality of life as well as on functional and 
cognitive abilities of the patients with PD, accurate tool with 
good validity and reliability to measure such symptoms is 
necessary. There is  a variety of tools to evaluate fatigue, 
including Fatigue Severity Scale (FSS), Fatigue Impact Scale 
(FIS) and Visual Analogue Scale to Evaluate Fatigue Severity 
(VAS for fatigue) (9). In spite of cross cultural adaptation of 
the mentioned scales in Iranian culture, the necessity of 
administrating a fatigue scale specific to patients with PD 
encouraged us to administer Parkinson Fatigue Scale (PFS-16) 
in the current project. PFS-16 designed by Brown et.al in 2005 
in order to measure the impact of fatigue on daily functions 
(10) is a valid tool c to quantify  fatigue. PFS-16 is a self-report 
scale consisting of the total number of 16 questions and two 
sub-scales including physical effects of fatigue experience (7 
questions) as well as fatigue impacts on daily functions (9 
questions).  The patients were supposed to answer the 
questions based on their feeling and experience of fatigue in 
the last two weeks (in two previous weeks) and to choose one 
of the response options for each question. The Likert scoring 
system consisting of main categories of agreement-
disagreement ("strongly disagree", "disagree", "do not agree or 
disagree", "agree" and "strongly agree") was applied to each 
item (11).  
There are different pieces of evidence  in order to investigate  
the application of PFS-16 and it is translated and cross cultural 
adapted to Sweden and Brazilian languages (12, 13). 
Translation, cross-cultural adaptation, face validity and 
content validity of the Persian version of the PFS-16 have been 
performed by Baghoori et.al. (14). In the current study we 
administered the Persian version of the PFS-16. 
There were two main reasons which motivated us to 
conduct the current study aiming at assessing the 
psychometric properties (validity and reliability) of the Persian 
version the PFS-16 to be administered in PD population in 
Iran. First of all, there are several linguistic and cultural 
differences among different countries which might affect the 
way of filling out the self-report scales and the validity of the 
scores. Second of all, the related literature lacked the 
investigation into the administration of the PFS-16 in patients 
with PD in Iran. 
Materials and Methods 
Participants 
The current study was conducted on the convenience sample 
of 70 patients with PD (17 females and 53 males; mean age: 
62.7±11.6) in Rasoul Akram hospital, Tehran, Iran during 
three months. To classify the motor functions of the 
participants, Hoen and Yahr (HY) Scale was used in the 
current study. HY scale is an effective and useful tool to classify 
the motor functions of the patients with PD. It classifies the 
motor function from stage 1 to 5 (15). Based on the modified 
version of Hoen and Yahr (HY) Scale, there were 23 persons at 
stage 1, 27 persons at stage 1.5, 11 persons at stage 2, 4 persons 
at stage 2.5 and 5 persons at stage 3  
On the one hand, having the ability to write and read, 
scoring higher than 23 in Mini-Mental status examination 
(MMSE) test (16), being fluent in Persian language, not 
consuming drugs affecting fatigue (e.g. Amantadine), and 
having the ability to perform the test in the drug "On" phase 
were considered as the main inclusion criteria. On the other 
hand, some other factors such as, the presence of other 
neurological disorders (e.g. stroke), the presence of orthopedic 
disorders (e.g. low back pain, arthritis), and the presence of 
diabetes or addiction based on the patient's report or 
physician's diagnosis were the key exclusion criteria of this 
study.  
We have used the Persian version of FSS, VAS, PDQ-8 and 
PFS-16 in the drug "On" phase in the present study. The study 
was approved by the ethics committee of Shahid Beheshti 
University of medical sciences. The participants completed the 
informed consent form prior to the study. In order to perform 
re-test, 50 of the participants were reexamined by PFS-16 in 
the same place and situation and by the same examiner after 7 
to 10 days following the baseline test.  
Tools  
Fatigue Severity Scale (FSS): 
This scale is one of the most common and effective tools to 
measure fatigue. FSS measures the physical aspect of fatigue 
and its impact on daily functions. Furthermore, this scale is 
based on a self-administered questionnaire with 9 items 
investigating the fatigue during the previous week (s). Scoring 
of each item ranges from 1 to 7 (1 indicates strong 
disagreement and 7 strong agreement). Higher total number 
indicates higher levels of fatigue (3, 17, 18). 
Visual analogue scale for fatigue (VAS-F): 
The fatigue VAS is comprised of a horizontal line usually 10 
centimeters in length. Using the line, respondents can specify 
their level of the subjective experience of fatigue by indicating 
a position along the continues line between two end-points 
(zero: lack of feeling of fatigue and 10: severe fatigue). The 
number of the marked position is scored (3, 19).  
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Table 1. Demographic Information (n=70) 
% Number results Variable 
24.3 17 Female 
Gender 
75.7 53 Male 
32.9 23 1 
Severity of disease 
38.6 27 1.5 
15.7 11 2 
5.7 4 2.5 
7.1 5 3 
28.6 20 Yes 
Family History 
71.4 50 No 
31.4 22 Right 
Affected Side 50 35 Left 
18.6 13 Both Sides 
8.6 6 Still working 
Occupation 45.7 32 Unemployed 
45.7 32 Retired 
68.6 48 Independent 
Level of Independence 25.7 18 Semi dependent 
5.7 4 Dependent 
31.4 22 Yes 
Use assistive devices 
68.6 48 No 
 
Table 2. Descriptive statistics of total score of Persian Version of Parkinson's Fatigue Scale 
Range Max Min SD Mean PES-16 total score results 
71 80 19 12.17 68.61 Test 
60 80 20 13.72 64.6 Re-Test 
 
Table 3. Test-retest reliability for each item of Persian Version of Parkinson's Fatigue Scale 
Agreement Kappa Item 
very good 0.90 1 
very good 1.00 2 
very good 0.81 3 
very good 0.90 4 
very good 0.80 5 
very good 0.84 6 
very good 0.86 7 
very good 0.84 8 
very good 0.85 9 
very good 0.87 10 
very good 0.86 11 
very good 0.79 12 
very good 0.76 13 
very good 0.87 14 
very good 0.81 15 
very good 0.96 16 
Psychometric properties of the persian version of parkinson fatigue scale                                                                                                                                 91 
 
Journal of Clinical Physiotherapy Research. 2017;2(2): 88-93 
Copyright © 2016 Shahid Beheshti University of Medical Sciences. All rights reserved. Downloaded from: http://journals.sbmu.ac.ir/physiotherapy/ 
 
 
Parkinson's disease questionnaire-8 (PDQ-8)  
The scale used is the short version of PDQ-39, includes 8 items 
in which each item reflects one of the sub-scales of PDQ-39. 
Fereshte Nejad et.al investigated the validity and the reliability 
of the scale in Persian language in 2014(2). 
Statistical Analysis: 
In order to assess the internal consistency of the Persian 
version of PFS-16, Chronbach's alpha coefficient was used in 
the present study. Internal consistency evaluates the general 
association of the items on the scale. A Cronbach's alpha of 0.8 
or greater indicates a good internal consistency, alpha between 
0.7-0.79 illustrates  an acceptable internal consistency and 
alpha of lower than 0.7 means an inacceptable internal 
consistency(20). We administered intra-class correlation 
coefficient (ICC) to assess the reliability. ICC of greater than 
0.8 is interpreted as a very good coefficient, between 0.6-0.8 as 
a good one, between 0.2-0.4 as a moderate one and lower than 
0.2 is interpreted as a poor coefficient(21). Moreover, in order 
to evaluate the test-retest reliability of the Persian version of 
PFS-16, Kappa coefficient was applied. Kappa of greater than 
0.75 is interpreted as a very good coefficient, between 0.4-0.75 
as a moderate one and lower than 0.4 is interpreted as a poor 
coefficient on the scale (22). Spearman’s rank correlation was 
calculated for the analysis of the relationship between PFS-16 
and FSS as well as PDQ-8 and VAS-F. The correlation result 
was interpreted according to the Munro's classification. Based 
on the Munro's classification, the coefficient between 0.9-1 is 
taken as a very high coefficient, between 0.7-0.89 as a high one, 
between 0.5-0.69 a moderate one and between 0.26-0.49 is 
interpreted as a low coefficient. Finally in order to assess the 
Minimum detectable change (MDC) resulted from the 
measurement error, we used MDC=1.96×√2×SEM formula 
with confidence interval of 0.95(23) (for this purpose Standard 
error of measurement (SEM) is equal to SD√1-ICC). 
Results 
Seventy patients suffering from PD (53 males and 17 females) 
with the average age of 62.7±11.6 participated in this study. 
Regarding the affected side, 22 of the participants had right-
sided symptoms, 35 had left-sided symptoms and the 
13remaining participants reported symptoms on both sides. 
Frequency and percentage frequency of the demographic 
variables are shown in table 1.  
The results indicated that Cronbach's alpha coefficient of 
the PFS-16 was 0.97. Thus, this scale had a very good internal 
consistency. Moreover, ICC of the Persian version of PFS-16 
was measured to be 0.97 which illustrated its good stability. 
Descriptive statistics of the Persian version of PFS-16 total 
score are demonstrated in table 2. 
Furthermore, in order to assess the test-retest reliability of 
the scale, Kappa coefficient was employed for each item of the 
PFS-16. Results showed that Kappa coefficient of 0.76-1 with 
the mean of 0.85 was obtained. Hence, PFS-16 has also a very 
good test-retest reliability. Kappa coefficient for each item of 
the Persian Version of PFS-16 is represented in table 3. 
In addition, the correlation between PFS-16 and the total 
score of FSS was tested in order to assess the validity of the 
Persian version of PFS-16. The result of the correlation 
between the total score of the Persian version of PFS-16 and 
the total score of FSS was significant (r: 0.58, P<0.001). To 
evaluate the criteria validity, we constructed convergent 
validity. The results of the correlations between the Persian 
version of PFS-16 items and the total score of VAS for fatigue 
(r: 0.49, P<0.001) and PDQ-8(r: 0.51, P<0.001) were 
significant. Finally, MDC (SEM) for the total score of PFS-16 
was measured to be 6.13 (2.21). 
Discussion 
Fatigue is one of the most common non-motor symptoms of 
patients with PD which prominently affects the quality of life 
of this population (24). In this regard, PFS-16 is a specific and 
valid tool  to measure fatigue in patients with PD (9). Thus, the 
aim of the current study was to assess the psychometric 
properties of the Persian version of PFS-16. Our results 
approved a very good internal consistency of the Persian 
version of PFS-16. This finding confirmed that PFS-16 exactly 
measured what it was conceptually designed for (i.e. fatigue). 
Moreover, this finding verified the clinical or laboratory usage 
of the total score of PFS-16 which was in line with the previous 
studies done by Brown and Grace (10, 11). Additionally, 
Kummer et.al. reported a Cronbach's alpha of 0.93 for the PFS-
16 (13). Furthermore, our results showed very good test-retest 
reliability of the PFS-16 (ICC: 0.97). This was also in line with 
the previous findings reported by Brown and Hagell (11, 12). 
Besides, the results of the current study indicated that Kappa 
coefficient for the Persian version of PFS-16 was between 0.76-
1 representing very good reliability. In a similar investigation, 
Brown also indicated  that the Kappa coefficient for the PFS-
16 was between 0.4-0.7 (11).  
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As there is no other valid tool specifically designed to 
measure fatigue (11) for the patients with PD, in this study we 
administered the most valid and useful tool  to measure the 
severity of fatigue named FSS in order to test the validity of 
PFS-16. Fereshte Nejad et.al. studied the validity and the 
reliability of the Persian version of FSS in a Persian PD 
population (18). Regarding the validity of the scale, our 
findings showed an association between Persian version of 
PFS-16 and FSS (r: 0.58) which indicated moderate validity for 
PFS-16. Moreover, we constructed convergent validity to 
measure the criteria validity. To do so, the correlation between 
the Persian version of PFS-16 and VAS for fatigue as well as the 
correlation between the Persian version of PFS-16 and PDQ-8 
were assessed. The findings represented low validity of the 
PFS-16 compared to VAS and moderate validity of the PFS-16 
in comparison with PDQ-8. In the similar investigation, Brown 
reported a strong correlation (r: 0.68) between the PFS-16 and 
VAS indicating good validity (11). In addition, Grace showed 
a strong association between PSF-16 and FSS (r: 0.84) and 
between PFS-16 and one question fatigue rating (FR) (r: 0.78) 
(10). Furthermore, Okuma investigated the correlation 
between PFS-16 and PDQ-8 as well as PDSS. They reported a 
medium (moderate) (r: 0.66) and poor (r:-0.48) correlation 
respectively (25). Besides, more recently, Hagell evaluated the 
correlation between PFS and FACIT-F and reported a 
coefficient correlation of-088 (12).  
Regarding MDC (SEM), the total score of PFS-16 was 
found to be 6.13 (2.21). As far as we know, this is the first study 
reporting this result for MDC in PFS-16.   
Limitations: 
The present study had several limitations. Firstly, our study 
had access to a small sample size because our sample was 
limited to the patients of just one hospital. Larger sample sizes 
in future similar investigations will probably enhance and 
improve the reliability of the findings, will reduce error of 
measurement and consequently will improve the reliability of 
the findings.  
Secondly, regarding the fatigue pathophysiology in patients 
with PD, it is considered to have several dimensions, but PFS-
16 assesses only the physical dimension of fatigue and fails to 
evaluate other dimensions. Thirdly, in the present 
investigation, patients with cognitive impairments were 
excluded from the study. To add to the literature in this field, 
it is better to compare fatigue between PD patients with and 
without cognitive problems. Moreover, our investigation was 
performed in "On" phase of drug. It could be recommended 
that future studies investigate fatigue in PD patients in off 
phase of drug too. 
Conclusion 
According to the results of this study, ultrasonography method 
could be considered as an appropriate method to evaluate the 
morphology of muscles in patients with FSHD. Furthermore, we 
might suggest this method as a suitable one in order to compare 
or to determine the effectiveness of different treatment methods. 
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